Treating patients with cancer and acute venous thromboembolism

References

• Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation. 2003;107(23 Suppl 1):I17–I21.
   PubMed Web of Science ®Google Scholar
• Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol. 2005;6:401–410.
   PubMed Web of Science ®Google Scholar
• Blom JW, Doggen CJM, Osanto S, et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293:715–722.
   PubMed Web of Science ®Google Scholar
• Otten HM, Mathijssen J, Ten Cate H, et al. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy. An underestimated phenomenon. Arch Intern Med. 2004;164:190–194.
   PubMed Web of Science ®Google Scholar
• Chew HK, Wun T, Harvey D, et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166:458–464.
   PubMed Web of Science ®Google Scholar
• Khorana AA, Francis CW, Culakova E, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5:632–634.
   PubMed Web of Science ®Google Scholar
• Akl EA, Kahale L, Neumann I, et al. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev. 2014 Jun 19;6:CD006649.
   Google Scholar
• Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia. Antithrombotic therapy and prevention of thrombosis, 9th ed.: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 suppl):e495S–e530S.
   PubMed Web of Science ®Google Scholar
• van Doormaal FF, Raskob GE, Davidson BL, et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thromb Haemost. 2009;101:762–769.
   PubMed Web of Science ®Google Scholar
• Farge D, Debourdeau P, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost. 2013;11:56–70.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Bohlke K, Khorana AA, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014. J Clin Oncol. 2015;33:654–656.
   PubMed Web of Science ®Google Scholar
• Mandalà M, Falanga A, Roila F. Management of venous thromboembolism (VTE) in cancer patients: ESMO clinical practice guidelines. Ann Oncol. 2011;22(Suppl 6):vi85–92.
   PubMed Web of Science ®Google Scholar
• Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100:3484–3488.
   PubMed Web of Science ®Google Scholar
• Lee AY, Levine MN, Baker RI, et al. Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146–153.
   PubMed Web of Science ®Google Scholar
• Akl EA, Kahale L, Barba M, et al. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev. 2014 Jul 8;7:CD006650.
   PubMedGoogle Scholar
• Lee AY, Kamphuisen PW, Meyer G, et al. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: A randomized clinical trial. JAMA. 2015;314:677–686.
   PubMed Web of Science ®Google Scholar
• Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease. Antithrombotic therapy and prevention of thrombosis, 9th ed.: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e419S–94S.
   PubMed Web of Science ®Google Scholar
• Vedovati MC, Germini F, Agnelli G, et al. Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis. Chest. 2015;147:475–483.
   PubMed Web of Science ®Google Scholar
• Francis CW, Kessler CM, Goldhaber SZ, et al. Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN study. J Thromb Haemost. 2015;13:1028–1035.
   PubMed Web of Science ®Google Scholar
• Napolitano M, Saccullo G, Malato A, et al. Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis: the Cancer-DACUS study. J Clin Oncol. 2014;32:3607–3612.
   PubMed Web of Science ®Google Scholar
• Koopman MMW, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med. 1996;334:682–687.
   PubMed Web of Science ®Google Scholar
• Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med. 1996;334:677–681.
   PubMed Web of Science ®Google Scholar
• Boccalon H, Elias A, Chalé JJ, et al. Clinical outcome and cost of hospital vs home treatment of proximal deep vein thrombosis with a low-molecular-weight heparin: the Vascular Midi-Pyrenees study. Arch Intern Med. 2000;160:1769–1773.
   PubMed Web of Science ®Google Scholar
• Siragusa S, Arcara C, Malato A, et al. Home therapy for deep vein thrombosis and pulmonary embolism in cancer patients. Ann Oncol. 2005;16(Suppl 4):iv 136–39.
   Google Scholar
• Ageno W, Grimwood R, Limbiati S, et al. Home-treatment of deep vein thrombosis in patients with cancer. Haematologica. 2005;90:220–224.
   PubMed Web of Science ®Google Scholar
• Squizzato A, Galli M, Dentali F, et al. Outpatient treatment and early discharge of symptomatic pulmonary embolism: a systematic review. Eur Respir J. 2009;33:1148–1155.
   PubMed Web of Science ®Google Scholar
• Aujesky D, Roy PM, Verschuren F, et al. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet. 2011;378:41–48.
   PubMed Web of Science ®Google Scholar
• Aujesky D, Obrosky DS, Stone RA, et al. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med. 2005;172:1041–1046.
   PubMed Web of Science ®Google Scholar
• Squizzato A, Donadini MP, Galli L, et al. Prognostic clinical prediction rules to identify a low-risk pulmonary embolism: a systematic review and meta-analysis. J Thromb Haemost. 2012;10:1276–1290.
   PubMed Web of Science ®Google Scholar
• Kline JA, Roy PM, Than MP, et al. Derivation and validation of a multivariate model to predict mortality from pulmonary embolism with cancer: the POMPE-C tool. Thromb Res. 2012;129:e194–9.
   PubMed Web of Science ®Google Scholar
• den Exter PL, Gómez V, Jiménez D, et al. A clinical prognostic model for the identification of low-risk patients with acute symptomatic pulmonary embolism and active cancer. Chest. 2013;143:138–145.
   PubMed Web of Science ®Google Scholar
• Dentali F, Ageno W, Becattini C, et al. Prevalence and clinical history of incidental, asymptomatic pulmonary embolism: a meta-analysis. Thromb Res. 2010;125:518–522.
   PubMed Web of Science ®Google Scholar
• Donadini MP, Dentali F, Squizzato A, et al. Unsuspected pulmonary embolism in cancer patients: a narrative review with pooled data. Intern Emerg Med. 2014;9:375–384.
   PubMed Web of Science ®Google Scholar
• O’Connell C, Razavi P, Ghalichi M, et al. Unsuspected pulmonary emboli adversely impact survival in patients with cancer undergoing routine staging multi-row detector computed tomography scanning. J Thromb Haemost. 2011;9:305–311.
   PubMed Web of Science ®Google Scholar
• Sahut D’Izarn M, Caumont-Prim A, Planquette B, et al. Risk factors and clinical outcome of unsuspected pulmonary embolism in cancer patients: a case–control study. J Thromb Haemost. 2012;10:2032–2038.
   PubMed Web of Science ®Google Scholar
• den Exter PL, van Roosmalen MJ, van den Hoven P, et al. Physicians’ management approach to an incidental pulmonary embolism: an international survey. J Thromb Haemost. 2013;11:208–213.
   PubMed Web of Science ®Google Scholar
• Donato AA, Khoche S, Santora J, et al. Clinical outcomes in patients with isolated subsegmental pulmonary emboli diagnosed by multidetector CT pulmonary angiography. Thromb Res. 2010;126:e266–e270.
   PubMed Web of Science ®Google Scholar
• Pena E, Kimpton M, Dennie C, et al. Difference in interpretation of computed tomography pulmonary angiography diagnosis of subsegmental thrombosis in patients with suspected pulmonary embolism. J Thromb Haemost. 2012;10:496–498.
   PubMed Web of Science ®Google Scholar
• Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol. 2003;21:3665–3675.
   PubMed Web of Science ®Google Scholar
• Savage KJ, Wells PS, Schulz V, et al. Outpatient use of low molecular weight heparin (Dalteparin) for the treatment of deep vein thrombosis of the upper extremity. Thromb Haemost. 1999;82:1008–1010.
   PubMed Web of Science ®Google Scholar
• Kovacs MJ, Kahn SR, Rodger M, et al. A pilot study of central venous catheter survival in cancer patients using low-molecular-weight heparin (dalteparin) and warfarin without catheter removal for the treatment of upper extremity deep vein thrombosis (The Catheter Study). J Thromb Haemost. 2007;5:1650–1653.
   PubMed Web of Science ®Google Scholar
• Tran H, Arellano M, Chamsuddin A, et al. Deep venous thromboses in patients with hematological malignancies after peripherally inserted central venous catheters. Leuk Lymphoma. 2010;51:1473–1477.
   PubMed Web of Science ®Google Scholar
• Debourdeau P, Farge D, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. J Thromb Haemost. 2013;11:71–80.
   PubMed Web of Science ®Google Scholar
• Schiffer CA, Mangu PB, Wade JC, et al. Central venous catheter care for the patient with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013;31:1357–1370.
   PubMed Web of Science ®Google Scholar
• Sousa B, Furlanetto J, Hutka M, et al. Central venous access in oncology: ESMO clinical practice guidelines. Ann Oncol. 2015;26(Suppl 5):v152–v168.
   Google Scholar
• Carrier M, Le Gal G, Cho R, et al. Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients. J Thromb Haemost. 2009;7:760–765.
   PubMed Web of Science ®Google Scholar
• Schulman S, Zondag M, Linkins L, et al. Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis. J Thromb Haemost. 2015;13:1010–1018.
   PubMed Web of Science ®Google Scholar
• Thatipelli MR, McBane RD, Hodge DO, et al. Survival and recurrence in patients with splanchnic vein thromboses. Clin Gastroenterol Hepatol. 2010;8:200–205.
   PubMed Web of Science ®Google Scholar
• Ageno W, Riva N, Schulman S, et al. Long-term clinical outcomes of splanchnic vein thrombosis: results of an international registry. JAMA Intern Med. 2015;175:1474–1480.
   PubMed Web of Science ®Google Scholar
• Valla DC. Hepatic venous outflow tract obstruction etiopathogenesis: Asia versus the West. J Gastroenterol Hepatol. 2004;19:S204–11.
   Google Scholar
• Darwish Murad S, Plessier A, Hernandez-Guerra M, et al. Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med. 2009;151:167–175.
   PubMed Web of Science ®Google Scholar
• Ageno W, Squizzato A, Togna A, et al. Incidental diagnosis of deep vein thrombosis in consecutive patients undergoing a CT scan of the abdomen: a retrospective cohort study. J Thromb Haemost. 2012;10:158–160.
   PubMed Web of Science ®Google Scholar
• Ageno W, Dentali F, Squizzato A. How I treat splanchnic vein thrombosis. Blood. 2014;124:3685–3691.
   PubMed Web of Science ®Google Scholar
• Ruff RL, Posner JB. Incidence and treatment of peripheral venous thrombosis in patients with glioma. Ann Neurol. 1983;13:334–336.
   PubMed Web of Science ®Google Scholar
• Altschuler E, Moosa H, Selker RG, et al. The risk and efficacy of anticoagulant therapy in the treatment of thromboembolic complications in patients with primary malignant brain tumors. Neurosurgery. 1990;27:74–76.
   PubMed Web of Science ®Google Scholar
• Levin JM, Schiff D, Loeffler JS, et al. Complications of therapy for venous thromboembolic disease in patients with brain tumors. Neurology. 1993;43:1111–1114.
   PubMed Web of Science ®Google Scholar
• Schiff D, De Angelis LM. Therapy of venous thromboembolism in patients with brain metastases. Cancer. 1994;73:493–498.
   PubMed Web of Science ®Google Scholar
• Schmidt F, Faul C, Dichgans J, et al. Low molecular weight heparin for deep vein thrombosis in glioma patients. J Neurol. 2002;249:1409–1412.
   PubMed Web of Science ®Google Scholar
• Choucair AK, Silver P, Levin VA. Risk of intracranial hemorrhage in glioma patients receiving anticoagulant therapy for venous thromboembolism. J Neurosurg. 1987;66:357–358.
   PubMed Web of Science ®Google Scholar
• Donato J, Campigotto F, Uhlmann EJ, et al. Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study. Blood. 2015;126:494–499.
   PubMed Web of Science ®Google Scholar
• Donadini MP, Ageno W, Antonucci E, et al. Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis: a patient-level meta-analysis. Thromb Haemost. 2014;111:172–179.
   PubMed Web of Science ®Google Scholar